Legal patent – Talk Bio

Actionable Insights Powered by AI

Moderna Wins UK Appeals Court in Covid-19 Patent Case Against Pfizer/BioNTech

1 month ago talkbio0Tagged appeal, BioNTech, court, COVID19 (disease), EP'949, infringement, Legal patent, legal victory, Moderna, Pfizer, UK, Vaccines

Moderna; Pfizer; BioNTech; UK Court of Appeal; COVID-19 vaccine; patent infringement; EP’949 patent; Comirnaty; legal victory

Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications

2 months ago talkbio0Tagged China, Clinical Trials, Dosage Forms, Ecosystem, global drug development, Industry, innovation, Legal patent, US-China competition

China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

3 months ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California

4 months ago talkbio0Tagged Broad Institute, Clustered Regularly Interspaced Short Palindromic Repeats, Eukaryotic Cells, Federal Circuit, Gene Modification, Intellectual Property, Legal patent, PTAB, University of California

CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

5 months ago talkbio0Tagged Halozyme, Legal patent, Merck, Subcutaneous Keytruda

Merck, Legal patent, Subcutaneous Keytruda, Halozyme

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

5 months ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Biopharma Layoff Trends in Q1 2025 and Outlook for Q2

5 months ago talkbio0Tagged Biopharma, Biopharma layoffs, Changing, Industry, Legal patent, Pharma, pharmaceutical employment, Q1 2025, Q2 layoff, regulatory, restructuring

Biopharma layoffs, Q1 2025 layoffs, biotech job cuts, pharma workforce reductions, restructuring, patent cliffs, regulatory challenges, Q2 layoff forecast, pharmaceutical employment trends, biopharma industry changes.

A closer look at pharmas top patent losses in 2025

6 months ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes

6 months ago talkbio0Tagged Alteogen, AstraZeneca, Enzymes, Halozyme, hyaluronidase, Legal patent, licensing agreement, Merck, Subcutaneous Cancer

AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme

Patent Dispute Erupts Over Merck’s Injectable Keytruda

6 months ago talkbio0Tagged Antineoplastic Agents, enzyme technology, Halozyme, Injectables, Keytruda, Legal patent, Merck

Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology